AB
ABNX.PA Abionyx Pharma SA
- Market cap
- EUR 67.9M
- P/E
- -
- P/B
- 4.30x
- ROE
- -122.8%
- Dividend yield
- -
- Fundamental score
- 0.3/5
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is ABNX.PA undervalued?
Graham numberThe Graham number of Abionyx Pharma SA cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Abionyx Pharma SA fundamental analysis
1 of 11 checks passedROE 0/2
The stock's ROE indicates a negative return (-48.22%) on shareholders' equity, suggesting poor financial performance.
ROA 0/2
The stock's ROA (-41.49%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.
PBV 0/2
The stock's high Price-to-Book Value (P/BV) ratio (4.66x) suggests it's overvalued, potentially making it an expensive investment.
DER 1/2
The stock maintains a fair debt to equity ratio (56%), indicating a reasonable balance between the money it owes and the ownership it possesses.
Revenue Growth 0/2
Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.
Net Profit Growth 0/2
The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity.
Assets Growth 0/2
Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.
Graham Number 0/1
The Graham number calculation reveals that this company's stock price is potentially inflated, implying that it may not be a desirable investment option.
Dividend Growth 0/2
The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.
Dividend 0/2
The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.
Buffet Intrinsic Value 0/1
Based on Warren Buffett's formula, the company's stock seems overpriced (-1), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Abionyx Pharma SA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Abionyx Pharma SA
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal, metabolic, and ophthalmic diseases in France and the United States. It operates through Research and Development Activities for the Development of Innovative Drugs; and Contract Research Organization (CRO) Activities segments. The company develops CER-001, a recombinant HDL mimetic biopharmaceutical in a Phase III trial for the treatment of lecithin cholesterol acyltransferase …
Full company profileAbionyx Pharma SA financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Abionyx Pharma SA annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 174K | 0.00 | 0.00 | 675K | 5.25M | 4.64M | 4.60M | 4.06M | 7.73M |
| Gross Profit | -53.0K | -43.0K | 174K | -72.0K | -80.0K | 259K | 636K | 618K | 844K | 376K | 88.0K |
| Operating Income | -24.0M | -6.64M | -7.05M | -2.53M | -3.59M | -5.95M | -4.11M | -3.41M | -5.57M | -6.26M | -10.4M |
| EBITDA | -27.0M | -5.80M | -6.27M | 1.75M | -2.39M | -7.42M | -4.01M | -4.53M | -5.27M | -5.70M | -8.89M |
| Net Income | -24.9M | -4.98M | -6.31M | 1.85M | -1.89M | -5.82M | -4.21M | -3.52M | -4.40M | -5.55M | -19.3M |
| EPS | -1.28 | -0.27 | -0.34 | 0.09 | -0.08 | -0.23 | -0.15 | -0.12 | -0.13 | -0.16 | -0.54 |
| Balance Sheet | |||||||||||
| Total Assets | 29.1M | 18.3M | 13.1M | 10.2M | 10.3M | 21.8M | 15.8M | 14.8M | 13.5M | 12.9M | 36.5M |
| Total Liabilities | 14.5M | 9.41M | 9.30M | 3.58M | 3.66M | 11.2M | 8.65M | 6.91M | 6.03M | 8.60M | 20.9M |
| Shareholders' Equity | 14.6M | 8.89M | 3.84M | 6.67M | 6.63M | 10.7M | 7.17M | 7.92M | 7.42M | 4.26M | 15.7M |
| Cash & Short-term Investments | 24.7M | 16.3M | 11.5M | 8.33M | 9.15M | 7.94M | 4.05M | 4.10M | 3.24M | 3.52M | 26.9M |
| Total Debt | 7.06M | 6.22M | 5.50M | 1.18M | 24.0K | 4.96M | 4.01M | 3.39M | 3.10M | 3.81M | 15.2M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -19.2M | -9.09M | -6.00M | -3.95M | -599K | -6.69M | -3.36M | -3.70M | -3.60M | -2.93M | -8.16M |
| Capital Expenditure | 5.00K | 213K | 23.0K | 103K | 148K | 166K | 175K | 130K | 76.0K | 242K | 200K |
| Free Cash Flow | -19.2M | -9.31M | -6.02M | -3.95M | -747K | -6.86M | -3.53M | -3.83M | -3.60M | -3.18M | -8.36M |
| Ratios | |||||||||||
| ROE | -170.2% | -56.0% | -164.3% | 27.7% | -28.5% | -54.5% | -58.7% | -44.4% | -59.3% | -130.3% | -122.8% |
| ROA | -85.6% | -27.2% | -48.0% | 18.0% | -18.3% | -26.7% | -26.6% | -23.7% | -32.7% | -43.1% | -52.7% |
| Net Profit Margin | - | - | -3,623.6% | - | - | -862.5% | -80.1% | -75.8% | -95.7% | -136.6% | -249.0% |
| Debt to Equity | 0.48x | 0.70x | 1.43x | 0.18x | 0.00x | 0.46x | 0.56x | 0.43x | 0.42x | 0.89x | 0.97x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Abionyx Pharma SA dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | EUR 3.97M | 0.16 | - |
| 2020 | EUR 1.55M | 0.07 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 66:65 on May 29, 2026.
Who owns Abionyx Pharma SA
- Insiders 28.95%
- Institutions 3.61%
- Public & others 67.44%
- Shares outstanding 43.8M
- Free float 22.7M
Abionyx Pharma SA company profile
- Company name
- Abionyx Pharma SA
- Ticker
- ABNX.PA
- ISIN
- FR0012616852
- Exchange
- Euronext Paris
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 49
- Fiscal year end
- December
- Address
- Building D2, Balma, France, 31130
- Phone
- 33 5 62 24 97 06
- Website
- abionyx.com
About Abionyx Pharma SA
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal, metabolic, and ophthalmic diseases in France and the United States. It operates through Research and Development Activities for the Development of Innovative Drugs; and Contract Research Organization (CRO) Activities segments. The company develops CER-001, a recombinant HDL mimetic biopharmaceutical in a Phase III trial for the treatment of lecithin cholesterol acyltransferase (LCAT) deficiency, as well as in a Phase II trial for the treatment of sepsis. It is also developing ABNX-100, a strategic extension into ophthalmology of CER-001 that is in preclinical trial for the treatment of uveitis. ABIONYX Pharma SA has a strategic partnership with Lille University Hospital"burn treatment center and intensive care unit to explore the potential of CER-001 in severe burn patients at high risk for sepsis. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was incorporated in 2005 and is headquartered in Balma, France.
Abionyx Pharma SA management
5- Sir Cyrille Tupin CPACEO, GM & Director · born 1977
- Prof. Christian Chavy MBAIndependent Director · born 1950
- Mr. Emmanuel De FougerouxAdministrative & Financial Director
- Ms. Constance Keyserling Peyrottes M.S.Vice President of Clinical, Regulatory Development & Operations · born 1961
- Mr. Laurent GuerciChief Digital & Innovation Officer